A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds

Journal of Alzheimer's Disease

Volumn 19, Issue 2, 2010, Pages 451-464

  Hansen, Elizabeth ^a   Krautwald, Martina ^b   MacZurek, Annette E ^b   Stuchbury, Grant ^a   Fromm, Phillip ^a   Steele, Megan ^b   Schulz, Oliver ^c   Garcia, Obdulio Benavente ^d   Castillo, Julian ^d   Körner, Heinrich ^a   Münch, Gerald ^b  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c Eurochem Feinchemie   (Germany)

^d 80320 Alcantarilla   (Spain)

Author keywords

Co culture; Inflammation; Microglia; Neurons; Neurotoxicity

Indexed keywords

ANTIINFLAMMATORY AGENT; APIGENIN; CARNOSIC ACID; CURCUMIN; CYTOKINE; ENHANCED GREEN FLUORESCENT PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEUROPROTECTIVE AGENT; NITROGEN; POLYPHENOL; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; UBIDECARENONE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DEATH; CELL LINE; COCULTURE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOWN REGULATION; DRUG IDENTIFICATION; ENZYME INHIBITION; FLUORESCENCE; GLUCOSE TRANSPORT; HIGH THROUGHPUT SCREENING; MICROGLIA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NERVE CELL CULTURE; NERVE CELL NECROSIS; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 77950503520     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1233     Document Type: Article

References (44)

1. Aisen PS, Davis KL (1994) Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 151, 1105-1113.
2. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R,Williams A (2002) Neuroinflammation in Alzheimer's disease and prion disease. Glia 40, 232-239.
3. Mancuso C, Scapagini G, Curro D, Giuffrida Stella AM, De Marco C, Butterfield DA, Calabrese V (2007) Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci 12, 1107-1123.
4. Giovannoni G, Heales SJ, Land JM, Thompson EJ (1998) The potential role of nitric oxide in multiple sclerosis. Mult Scler 4, 212-216.
5. Stoll G, Jander S, Schroeter M (1998) Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol 56, 149-171.
6. Wong A, Dukic-Stefanovic S, Gasic-Milenkovic J, Schinzel R, Wiesinger H, Riederer P, Münch G (2001) Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. Eur J Neurosci 14, 1961-1967.
7. Brown GC (2007) Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem Soc Trans 35, 1119-1121.
8. Weisman D, Hakimian E, Ho GJ (2006) Interleukins, inflammation, and mechanisms of Alzheimer's disease. Vitam Horm 74, 505-530.
9. Brown GC, Bal-Price A (2003) Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 27, 325-355.
10. Moreira PI, Smith MA, Zhu X, Nunomura A, Castellani RJ, Perry G (2005) Oxidative stress and neurodegeneration. Ann N Y Acad Sci 1043, 545-552.
11. Hensley K, Floyd RA (2002) Reactive oxygen species and protein oxidation in aging: a look back, a look ahead. Arch Biochem Biophys 397, 377-383.
12. Bales KR, Du Y, Dodel RC, Yan GM, Hamilton-Byrd E, Paul SM (1998) The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Brain Res Mol Brain Res 57, 63-72.
13. Gasic-Milenkovic J, Dukic-Stefanovic S, Deuther-Conrad W, Gartner U, Münch G (2003) beta-Amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon -gamma and advanced glycation endproducts' in a murine microglia cell line. Eur J Neurosci 17, 813-821.
14. Korhonen R, Lahti A, Kankaanranta H, Moilanen E (2005) Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy 4, 471-479.
15. Huber A, Stuchbury G, Burkle A, Burnell J, Münch G (2006) Neuroprotective therapies for Alzheimer's disease. Curr Pharm Des 12, 705-717.
16. Behl C (2002) Neuroprotective strategies in Alzheimer's disease. Adv Exp Med Biol 513, 475-496.
17. Stuchbury G,Münch G (2005) Alzheimer's associated inflammation, potential drug targets and future therapies. J Neural Transm 112, 429-453.
18. Münch G, Gasic-Milenkovic J, Dukic-Stefanovic S, Kuhla B, Heinrich K, Riederer P, Huttunen HJ, Founds H, Sajithlal G (2003) Microglial activation induces cell death, inhibits neurite outgrowth and causes neurite retraction of differentiated neuroblastoma cells. Exp Brain Res 150, 1-8.
19. Gibbons HM, Dragunow M (2006) Microglia induce neural cell death via a proximity-dependent mechanism involving nitric oxide. Brain Res 1084, 1-15.
20. Wang J (2009) Comprehensive assessment of ADMET risks in drug discovery. Curr Pharm Des 15, 2195-2219.
21. Wan H, Holmen AG (2009) High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery. Comb Chem High Throughput Screen 12, 315-329.
22. Pendieton R, Ensum, L. (2004) in: The global college of neuroprotection and neurodegeneration: annual conference 2004 (Switzerland), pp. 1-22.
23. Shanmugam K, Holmquist L, Steele M, Stuchbury G, Berbaum K, Schulz O, Benavente Garcia O, Castillo J, Burnell J, Garcia Rivas V, Dobson G, Münch G (2008) Plant-derived polyphenols attenuate lipopolysaccharide-induced nitric oxide and tumour necrosis factor production in murine microglia and macrophages. Mol Nutr Food Res 52, 427-438.
24. Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF, Lin JK (1999) Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20, 1945-1952.
25. Patil CS, Singh VP, Satyanarayan PS, Jain NK, Singh A, Kulkarni SK (2003) Protective effect of flavonoids against aging- and lipopolysaccharide-induced cognitive impairment in mice. Pharmacology 69, 59-67.
26. Escuder B, Torres R, Lissi E, Labbe C, Faini F (2002) Antioxidant capacity of abietanes from Sphacele salviae. Nat Prod Lett 16, 277-281.
27. Satoh S, Shindoh M, Min JZ,Toyo'oka T, Fukushima T, Inagaki S (2008) Selective and sensitive determination of lipoyllysine (protein-bound alpha-lipoic acid) in biological specimens by high-performance liquid chromatography with fluorescence detection. Anal Chim Acta 618, 210-217.
28. Lenaz G, Bovina C, D'Aurelio M, Fato R, Formiggini G, Genova ML, Giuliano G, Merlo Pich M, Paolucci U, Parenti Castelli G,Ventura B (2002) Role of mitochondria in oxidative stress and aging. Ann N Y Acad Sci 959, 199-213.
29. Masuda T, Maekawa T, Hidaka K, Bando H, Takeda Y, Yamaguchi H (2001) Chemical studies on antioxidant mechanism of curcumin: analysis of oxidative coupling products from curcumin and linoleate. J Agric Food Chem 49, 2539-2547.
30. Lim CS, Jin DQ, Mok H, Oh SJ, Lee JU, Hwang JK, Ha I, Han JS (2005) Antioxidant and antiinflammatory activities of xanthorrhizol in hippocampal neurons and primary cultured microglia. J Neurosci Res 82, 831-838.
31. Kim HY, Park EJ, Joe EH, Jou I (2003) Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J Immunol 171, 6072-6079.
32. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21, 8370-8377.
33. Baum L, Ng A (2004) Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis 6, 367-377; discussion 443-1369
34. Smith DG, Cappai R, Barnham KJ (2007) The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta 1768, 1976-1990.
35. Scalbert A, Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130, 2073S-2085S.
36. Cole GM, Teter B, Frautschy SA (2007) Neuroprotective effects of curcumin. Adv Exp Med Biol 595, 197-212.
37. Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH (2007) Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 853, 183-189.
38. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4, 807-818.
39. Maurer K, Ihl R, Dierks T, Frolich L (1997) Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res 31, 645-655.
40. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336, 1216-1222.
41. Klatte ET, Scharre DW, Nagaraja HN, Davis RA, Beversdorf DQ(2003) Combination therapy of donepezil and vitamin E in Alzheimer disease. Alzheimer Dis Assoc Disord 17, 113-116.
42. Adair JC, Knoefel JE, Morgan N (2001) Controlled trial of Nacetylcysteine for patients with probable Alzheimer's disease. Neurology 57, 1515-1517.
43. Hager K, Kenklies M, McAfoose J, Engel J, Münch G (2007) Alpha-lipoic acid as a new treatment option for Alzheimer's disease - a 48 months follow-up analysis. J Neural Transm Suppl, 189-193.
44. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH,Mok V(2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28, 110-113.